Amoxicillin-Clavulanate for Skin and Soft Tissue Infections
Amoxicillin-clavulanate 875/125 mg twice daily is the appropriate first-line oral antibiotic for animal or human bite wounds requiring antimicrobial coverage against both aerobic and anaerobic bacteria 1.
Primary Indication: Bite Wounds
Amoxicillin-clavulanate has a specific, guideline-supported role in skin and soft tissue infections, but this is narrowly defined. The 2014 IDSA guidelines explicitly recommend it for:
- Animal bite wounds requiring antimicrobial therapy
- Human bite wounds requiring antimicrobial therapy
The rationale is that bite wounds require coverage of both aerobic bacteria (including Pasteurella multocida from animal bites and Staphylococcus aureus) and anaerobic organisms from oral flora 1.
Dosing for Bite Wounds
- Adults: Amoxicillin-clavulanate 875/125 mg orally twice daily 1, 2
- Pediatric patients ≥40 kg: Use adult dosing 2
- Pediatric patients <40 kg: Dose based on amoxicillin component at 45 mg/kg/day divided every 12 hours for more severe infections 2
- Duration: Typically 3-5 days for preemptive therapy in high-risk bite wounds 1
Critical dosing caveat: Take at the start of meals to enhance clavulanate absorption and minimize GI intolerance 2. The twice-daily regimen is preferred over three-times-daily dosing as it significantly reduces diarrhea 3.
NOT Recommended for Most Other SSTIs
For the majority of skin and soft tissue infections, amoxicillin-clavulanate is not the guideline-recommended choice:
Non-Purulent Cellulitis
The IDSA guidelines recommend antibiotics targeting streptococci alone for typical cellulitis without systemic signs 1. This means:
- Simple penicillin or cephalexin are preferred
- Amoxicillin-clavulanate provides unnecessary anaerobic coverage and the clavulanate component adds no benefit for streptococcal cellulitis
Purulent Infections (Abscesses)
- Primary treatment is incision and drainage, not antibiotics 1
- When antibiotics are needed, coverage must target MRSA (methicillin-resistant S. aureus)
- Amoxicillin-clavulanate misses MRSA entirely 1
- Appropriate agents include trimethoprim-sulfamethoxazole, doxycycline, or clindamycin
Severe/Necrotizing Infections
For severe infections with systemic signs or necrotizing fasciitis, the guidelines recommend:
- Vancomycin plus piperacillin-tazobactam or a carbapenem 1
- Not amoxicillin-clavulanate, which lacks adequate gram-negative and MRSA coverage
Special Populations Where It May Be Considered
The French pediatric literature 4, 5 suggests amoxicillin-clavulanate as first-line for severe pediatric skin infections in settings with low MRSA prevalence. However, this contradicts the IDSA guidelines and reflects regional resistance patterns in France. In North America with higher MRSA rates, this approach is not appropriate.
Renal Dosing Adjustments
For patients with renal impairment 2:
- GFR <30 mL/min: Do not use 875/125 mg dose; use 500/125 mg every 12 hours
- GFR <10 mL/min: 500/125 mg every 24 hours
- Hemodialysis: 500/125 mg every 24 hours with additional dose during and after dialysis
Key Pitfalls to Avoid
- Do not use for routine cellulitis - this drives unnecessary resistance and provides no clinical benefit over simpler beta-lactams
- Do not use for purulent abscesses - it misses MRSA, the primary pathogen
- Do not substitute tablet strengths - the 250/125 mg and 500/125 mg tablets contain the same amount of clavulanate (125 mg), so two 250 mg tablets ≠ one 500 mg tablet 2
- Do not use in severe infections - inadequate spectrum for polymicrobial necrotizing infections
The bottom line: Amoxicillin-clavulanate has a narrow but important role in bite wound management, but it is not a broad-spectrum solution for most skin and soft tissue infections where simpler or more targeted antibiotics are preferred.